How Long Does It Take for Semaglutide to Suppress Appetite?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Most patients notice some appetite suppression within 2 to 5 days of their first 0.25 mg semaglutide dose, peaking around days 3 to 5 after each weekly injection.
• Steady-state plasma levels are reached after 4 to 5 weeks, when appetite effects become consistent throughout the week rather than peaking and dipping.
• Stronger appetite suppression typically appears at the 0.5 mg, 1 mg, and 2.4 mg titration steps, with each dose increase producing a fresh wave.
• Semaglutide's half-life is about 7 days. Levels build over 5 weekly injections to reach 95% of steady state.
• If appetite suppression is weak or absent after 4 to 6 weeks, the dose may be too low, the injection technique may be off, or the medication may have lost potency from improper storage.

Direct answer (40-60 words, snippet-optimized)

Most patients notice appetite suppression from semaglutide within 2 to 5 days of their first 0.25 mg dose. The strongest weekly suppression peaks at days 3 to 5 post-injection. Consistent week-long suppression appears around week 4 to 5, when steady-state plasma levels are reached after 5 weekly doses.

Table of contents

1. The 30-second answer
2. The mechanism behind the slowdown
3. Day-by-day timeline after your first dose
4. Why appetite peaks 2 to 3 weeks in
5. Why dose escalations create new waves
6. The full titration timeline
7. What to expect at each dose step
8. If you're not feeling appetite suppression
9. How food choices interact with the appetite effect
10. When the effect plateaus
11. FAQ
12. Sources
13. Footer disclaimers

The mechanism behind the slowdown

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a gut hormone the body releases naturally after meals. The molecule binds to GLP-1 receptors in three places that affect appetite: the pancreas (releasing insulin), the stomach and intestines (slowing gastric emptying), and the brain (specifically the arcuate nucleus and area postrema, which regulate hunger and satiety).

The two mechanisms most patients feel as "appetite suppression" are:

1. Slowed gastric emptying. Food sits in the stomach longer, so you feel full sooner during a meal and stay full longer between meals. This is a peripheral effect, mediated by GLP-1 receptors in the gut.
2. Brain-level satiety signaling. Semaglutide crosses the blood-brain barrier (a small fraction does, enough to be active centrally) and modulates hypothalamic circuits that control food intake. This is what reduces "food noise," the constant background thinking about food many patients describe.

Both effects appear quickly because they don't require the medication to do something gradual; they're active as soon as plasma levels reach a threshold. The reason the full effect takes 4 to 5 weeks isn't that the mechanism is slow, but that semaglutide accumulates over 5 weekly doses before plasma levels are stable enough to produce consistent suppression.

Day-by-day timeline after your first dose

Here's what most patients experience week by week on the standard 0.25 mg starting dose:

Day 1 (injection day): Most patients feel little or nothing the first 24 hours. A few report mild nausea or a vague feeling of "not really hungry" by evening, especially if they injected in the morning.

Days 2 to 3: Plasma levels rise toward initial peak (semaglutide's tmax is 1 to 3 days). Appetite suppression starts to be noticeable. Many patients report meals feeling 20 to 30% smaller than normal. Mild nausea is common, especially with rich or fatty foods.

Days 3 to 5: Peak weekly effect for the first dose. Patients often describe this window as "actually thinking about food less" rather than just feeling full faster. Constipation may start in this window for some patients, since slower gastric emptying extends to slower intestinal transit.

Days 5 to 7: Plasma levels begin declining as the next dose approaches. Appetite may return slightly, and patients sometimes feel "hungry again" by day 6 to 7. This rebound is normal and gets smaller as steady-state builds.

Day 7 (next injection): The cycle restarts, but on top of residual semaglutide from the previous week. Each subsequent injection lands on a higher baseline.

Why appetite peaks 2 to 3 weeks in

Semaglutide accumulates with weekly dosing because its half-life is about 7 days, longer than the dosing interval. Each injection adds to what's already in the system, until elimination matches input around week 5.

Mathematically, with a 7-day half-life and once-weekly dosing:

• After dose 1: plasma reaches initial peak, then drops by half by dose 2
• After dose 2: plasma reaches a higher peak (about 1.5x the dose 1 peak), drops less between doses
• After dose 3: peak is about 1.75x dose 1 peak
• After dose 4: peak is about 1.875x dose 1 peak
• After dose 5: peak is about 1.94x dose 1 peak (essentially at steady state)

This is why most patients describe weeks 3 to 5 as a meaningfully different experience from week 1. Plasma levels are nearly double what they were at the start, which is why appetite suppression intensifies even at the same dose.

After steady state is reached, the peak-trough swing flattens. Instead of a sharp peak at days 3 to 5 and a clear drop by day 7, patients feel more uniform suppression across the entire week.

Why dose escalations create new waves

The standard semaglutide titration schedule (0.25 mg, 0.5 mg, 1 mg, then 1.7 mg or 2.4 mg) creates a stepped pattern of appetite suppression. Each escalation produces a fresh wave that builds over the next 4 weeks.

When you escalate from 0.25 mg to 0.5 mg, your plasma levels start climbing toward a new, higher steady-state. The increased appetite suppression typically becomes obvious 7 to 14 days after the first higher-dose injection, because:

• Day 1 to 7 of the new dose: levels are only modestly higher than the prior steady-state.
• Day 8 to 21: each subsequent injection adds more, levels approach the new steady-state.
• Day 28+: new steady-state reached, full effect of the new dose felt.

This is also why side effects often re-appear or intensify briefly after each dose escalation. Nausea that resolved at 0.25 mg may return for 7 to 14 days after moving to 0.5 mg, then settle as the body adapts.

For patients who plateau on appetite suppression at one dose, the move to the next dose often produces a noticeable refresh. This is the dose-response curve at work, and it's why titration schedules exist.

For more on dose math, see our dosing math overview.

The full titration timeline

Standard semaglutide titration for weight management (Wegovy schedule):

Weeks	Dose	What to expect
1-4	0.25 mg	Mild appetite suppression by week 2, settles by week 4
5-8	0.5 mg	New wave of suppression, brief return of nausea
9-12	1.0 mg	Stronger suppression, often the dose where "food noise" drops sharply
13-16	1.7 mg	Continued strengthening, fewer hunger windows
17+	2.4 mg	Maintenance dose, full effect

Standard semaglutide titration for diabetes (Ozempic schedule):

Weeks	Dose	What to expect
1-4	0.25 mg	Same as above
5-8	0.5 mg	Same as above
9-12+	1.0 mg	Often a long-term maintenance dose
13+ (optional)	2.0 mg	Higher diabetes dose

The full titration to 2.4 mg takes a minimum of 17 weeks. For most patients, the strongest functional appetite suppression appears between weeks 9 and 16, when they're settling into the 0.5 to 1 mg range. The further escalations to 1.7 and 2.4 mg add incremental effect, but the largest week-over-week change in appetite often happens earlier in the titration.

What to expect at each dose step

0.25 mg: Starter dose. Designed for tolerability, not therapeutic effect. Most patients feel some appetite reduction (meals feel 15 to 25% smaller, snacking decreases), but it's a glimpse of what's coming, not the full experience. Some patients feel almost nothing at this dose.

0.5 mg: First therapeutic dose. Most patients describe this as the first dose where appetite suppression feels meaningful. Daily food intake often drops 20 to 30% without conscious effort. Many find their preferred foods change (less interest in sweets, less interest in heavy fats).

1.0 mg: Reliable maintenance dose. Strong appetite suppression for most patients. The "food noise" effect is often most pronounced here. Meal portions shrink further. Many type 2 diabetes patients are kept at 1.0 mg long-term.

1.7 mg: Intermediate Wegovy dose. Continued strengthening of effects. Some patients reach goal weight at this dose and don't need to escalate further.

2.4 mg: Maintenance Wegovy dose. Strongest appetite suppression. Most patients on this dose describe feeling full almost continuously, with active effort sometimes needed to eat enough to support training and lean mass.

2.0 mg (Ozempic): A separate ceiling for the diabetes-indicated product. Slightly weaker appetite suppression than 2.4 mg Wegovy, in line with the 0.4 mg dose difference.

For more on results timelines, see our zepbound timeline guide.

If you're not feeling appetite suppression

A meaningful number of patients (estimated 5 to 15%) report little or no appetite suppression on semaglutide. The common causes:

1. Dose too low. 0.25 mg is below the therapeutic threshold for many patients. If you've completed 4 weeks at 0.25 mg with no effect, the move to 0.5 mg often resolves it. Wait at least 2 weeks at the new dose before judging.

2. Injection technique issue. A subcutaneous injection that ends up intramuscular (deep injection in lean tissue) can change absorption. A pen that wasn't fully primed, or a dose that wasn't fully delivered, gives a partial dose. Confirm technique with your provider.

3. Storage problem. Semaglutide must stay refrigerated (36 to 46°F) until first use, then can be at room temperature for up to 28 days. Repeated temperature cycling, freezing, or extended room-temperature exposure degrades the peptide. If your medication has been mishandled, potency drops.

4. Genetic variation. A subset of patients are GLP-1 "non-responders" or "low-responders" due to GLP-1 receptor polymorphisms. These patients may benefit more from tirzepatide (which adds a GIP mechanism) than semaglutide.

5. Underlying conditions. Hyperthyroidism, certain medications (steroids, atypical antipsychotics), and unmanaged binge eating disorder can blunt the felt effect of GLP-1 medications. Worth a clinical review.

6. Time. A real but small subset of patients describe a "delayed bloom" where appetite suppression is mild for the first 4 to 8 weeks and then strengthens at week 10 to 12. Persistence sometimes pays off.

If you're 6 to 8 weeks into therapy at 0.5 mg or higher with no appetite change, talk to your provider. Don't quit silently; non-response is data, and there are reasonable next steps.

How food choices interact with the appetite effect

Semaglutide changes both how much food you want and what kinds of food appeal to you. Common patterns reported by patients:

• Sugary foods become less appealing. Many patients describe feeling "off" or queasy after eating sugar that previously felt fine.
• Fatty foods slow you down. Slowed gastric emptying is most pronounced with fat. A fatty meal can sit heavily for hours.
• Lean protein is easiest. Protein-forward meals tend to feel comfortable and produce sustained satiety.
• Liquid calories sneak in. Drinks (smoothies, juices, alcoholic beverages) bypass the gastric-emptying brake and can erode the calorie deficit semaglutide creates.

Working with the medication: front-load protein, eat smaller meals more frequently if needed, hydrate more than usual, and watch for liquid calories. A patient on 1 mg semaglutide who eats a 2,000-calorie smoothie hasn't really used the medication's benefit.

For specific diet approaches, see our protein and weight loss guide.

When the effect plateaus

Appetite suppression strengthens through the titration schedule and then plateaus. Most patients describe the pattern as:

• Weeks 1 to 4: noticeable effect builds
• Weeks 5 to 12: effect strengthens with each titration
• Weeks 13 to 24: strongest effect, weight loss accelerates
• Months 6 to 12: effect plateaus, weight loss continues but slows
• Months 12+: maintenance phase

The "tolerance" question comes up often: does semaglutide stop working? In trial data (STEP 1, STEP 5), weight loss continues for 18 to 24 months before plateauing, then weight is maintained at the new lower set point. The appetite suppression effect doesn't disappear; what plateaus is the rate of weight loss as the body reaches a new equilibrium.

If appetite seems to weaken after several months on a stable dose, possible reasons:

• Real biological adaptation. Some patients do see the effect soften slightly over time. The dose may need to be re-evaluated.
• Dietary drift. Calorie intake may have crept up gradually as confidence built. Track intake for a week to check.
• Sleep, stress, or training load changes. All of these affect appetite independently of medication.

A 2 to 3 week dip in appetite suppression isn't usually meaningful. A 6 to 8 week change usually is.

FAQ

How long does it take for semaglutide to suppress appetite? Most patients notice some appetite suppression within 2 to 5 days of their first 0.25 mg dose, peaking at days 3 to 5 post-injection. Consistent week-long suppression appears around week 4 to 5, when steady-state plasma levels are reached after about 5 weekly injections.

Why don't I feel anything in the first week? Plasma levels are still building during week 1. Semaglutide's half-life is about 7 days, so the medication takes 5 weeks of weekly dosing to reach 95% of its steady-state level. The first dose alone can't produce the full effect.

When do I notice the strongest effect each week? Days 3 to 5 after each weekly injection are typically when you'll feel the strongest suppression, since plasma levels peak in that window. Days 6 to 7 may have a slight rebound in appetite as levels start to fall before the next dose.

Is appetite suppression at 0.25 mg normal? Yes, but it's usually mild. The 0.25 mg starter dose is designed for tolerability, not full therapeutic effect. Most patients feel a 15 to 25% reduction in meal size and some reduction in snacking. Stronger effects come with the 0.5 mg, 1 mg, and 2.4 mg steps.

Why did my appetite come back after a few weeks? Two common reasons: you're approaching steady-state plateau (normal and expected) or you've adapted to the dose. If you're still in the titration phase, the next dose escalation usually produces a fresh wave. If you're at maintenance dose and effect has weakened, talk to your provider about evaluation.

Can I tell if semaglutide is working in the first week? Sometimes. About 60 to 70% of patients report some noticeable appetite change within 5 days of the first dose. The other 30 to 40% don't feel a clear effect until week 2 or 3. Both patterns are within normal range.

Does semaglutide work the same on all foods? No. Slowed gastric emptying is most pronounced with high-fat foods. Liquid calories (juices, smoothies, alcohol) bypass the gastric brake more easily. Protein-forward meals tend to feel comfortable while still providing strong satiety. The brain-level "food noise" reduction affects all foods broadly.

What if I haven't lost weight at 4 weeks? Normal. Most patients lose 1 to 4 pounds in the first 4 weeks at 0.25 mg, but some lose nothing or gain a small amount due to water retention or unchanged eating habits. Significant weight loss typically begins between weeks 4 and 12, after escalation to 0.5 to 1 mg.

Does timing my injection day matter for appetite suppression? Not much. The suppression peak (days 3 to 5) shifts based on injection day, but the weekly cycle is the same. Some patients prefer Sunday or Monday injection so the strongest suppression aligns with weekday discipline; others prefer Friday so it covers weekend social eating.

Will eating more help me feel less suppressed? Within reason, yes. Patients who under-eat for several days can feel more nauseated and more "stuck" full. Eating regular, protein-forward meals, even when not very hungry, tends to keep the GI system moving and can reduce the queasy-stuck feeling.

Can I drink coffee or alcohol on semaglutide? Coffee usually fine; many patients drink less than before because the appetite suppression carries over to caffeine cravings. Alcohol is more variable; many patients find their tolerance drops sharply, and a single drink can hit harder than usual. Slowed gastric emptying changes how alcohol absorbs.

Does compounded semaglutide work the same way? The molecule is the same, so the mechanism is the same. Compounded semaglutide produced by a state-licensed compounding pharmacy should produce comparable appetite suppression on a milligram-for-milligram basis. Compounded medications are not FDA-approved and aren't interchangeable with brand-name products.

Sources

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
3. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28:2083-2091.
4. Kapitza C, et al. Pharmacokinetics, pharmacodynamics, and tolerability of multiple-dose oral semaglutide. J Clin Pharmacol. 2015;55:497-504.
5. Marbury TC, et al. Pharmacokinetics and tolerability of a single dose of semaglutide. Clin Pharmacokinet. 2017;56:1381-1390.
6. Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight. Diabetes Obes Metab. 2017;19:1242-1251.
7. Friedrichsen M, et al. The effect of semaglutide 2.4 mg on energy intake, appetite, and gastric emptying. Diabetes Obes Metab. 2021;23:754-762.
8. Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021;46:101102.
9. U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information.
10. U.S. Food and Drug Administration. Ozempic (semaglutide) prescribing information.
11. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). N Engl J Med. 2016;375:1834-1844.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.